
Opinion|Videos|August 21, 2024
Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL
Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- A 32-year-old female with a history of migraines and anxiety presented to the Emergency Department with a one-month history of fatigue and weakness and a two-day history of spontaneous bruising.
- The patient had been undergoing an outpatient workup for anemia with her primary care physician.
- In the ED, blood counts were noted to be abnormal. White blood cell count was 2.9k with neutrophils 8% and lymphocytes 89%, hemoglobin 4.2 g/dL, and platelet count 6k.
- Bone marrow examination revealed cellularity of 100% with 80% blasts expressing CD19, CD10, CD34, HLA-DR, CD38, CD43, CD22, and CD24. FISH and PCR for the BCR-ABL translocation were negative.
- No Ph-like abnormalities were detected.
- No malignant cells were identified in the cerebrospinal fluid.
- The patient was initiated on treatment per CALGB 10403.
Advertisement
Related to this article

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5


